Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Published version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Purpose: Transforming growth factor β (TGFβ) is a pleiotropic cytokine that affects tumor growth, metastasis, stroma, and immune response. We investigated the therapeutic efficacy of anti–TGFβ receptor II (TGFβ RII) antibody in controlling metastasis and tumor growth as well as enhancing antitumor immunity in preclinical tumor models. Experimental Design: We generated neutralizing antibodies to TGFβ RII and assessed the antibody effects on cancer, stroma, and immune cells in vitro. The efficacy and mechanism of action of the antibody as monotherapy and in combination with chemotherapy in suppression of primary tumor growth and metastasis were evaluated in several tumor models. Results: Anti–TGFβ RII antibody blocked TGFβ RII binding to TGFβ 1, 2, and 3, and attenuated the TGFβ-mediated activation of downstream Smad2 kinase, invasion of cancer cells, motility of endothelial and fibroblast cells, and induction of immunosuppressive cells. Treatment with the antibody significantly suppressed primary tumor growth and metastasis and enhanced natural killer and CTL activity in tumor-bearing mice. Immunohistochemistry analysis showed cancer cell apoptosis and massive necrosis, and increased tumor-infiltrating T effector cells and decreased tumor-infiltrating Gr-1+ myeloid cells in the antibody-treated tumors. Fluorescence-activated cell sorting analysis indicated the significant reduction of peripheral Gr-1+/CD11b+ myeloid cells in treated animals. Concomitant treatment with the cytotoxic agent cyclophosphamide resulted in a significantly increased antitumor efficacy against primary tumor growth and metastasis. Conclusions: These preclinical data provide a foundation to support using anti–TGFβ RII antibody as a therapeutic agent for TGFβ RII–dependent cancer with metastatic capacity. Clin Cancer Res; 16(4); 1191–205
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early examples showed reduction of breast cancer metastasis in response to anti-TGF-β antibodies or soluble TβRII-based ligand trap306,326,327.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [306]
In the citing paper
“Other inhibitors are designed as soluble, high-affinity ligand traps to prevent TGF-β binding to its receptors306,307.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [306]
In the citing paper
“The utility of a TGF-β ligand trap in blocking tumor dissemination was first shown in mice that express such a trap and were challenged by intravenous or orthotopic implantation of breast carcinoma cells306.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [306]
In the citing paper
“LY3022859, an antibody against TGF‐β receptor 2, showed survival benefits in mouse models [163].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [163]
Citations
Cites
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 1×
“Studies based on genetic modification and the use of TGFβ signaling inhibitors have provided considerable knowledge for understanding the mechanisms of TGFβ signaling–modulated pathogenesis in tumor, metastasis, angiogenesis, and immunosuppression (4, 5, 18).”
BackgroundTGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×
“Gr-1+/CD11b+ myeloid cells have a seminal role in promoting metastasis and angiogenesis in tumor stroma and in mediating immunosuppression during tumor progression (11, 13, 15).”
BackgroundTGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Transforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
Marie, J. C., Letterio, J. J., Gavin, M., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 985
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Metadata
- Authors
- Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., Burtrum, D., Wang, S., Surguladze, D., Ng, S., Griffith, H., Balderes, P., Doody, J., Schwartz, J. D., Youssoufian, H., Rowinsky, E. K., Ludwig, D. L., Witte, L., Zhu, Z., & Wu, Y.
- Affiliations
- Authors' Affiliations: Departments of 1Antibody Technology & Immunology, 2Cell Biology, 3Preclinical Pharmacology, 4Molecule and Cell Engineering, 5Protein Science, 6Clinical Research, and 7Research, ImClone Systems, New York, New York
- Corresponding author
- Wu, Yan
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2010-02-15
- Volume
- 16
- Issue
- 4
- Pages
- 1191-1205
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2148543405
- Cited by
- 123
- References
- 49
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 13 · 2018: 3 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 9 · 2013: 9 · 2012: 9
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Toronto
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- TGFBR2, TGF-beta signaling, metastasis, primary tumor growth, antitumor immunity, tumor stroma, Smad2/3 signaling, tumor invasion, natural killer cells, cytotoxic T lymphocytes, neutralizing antibodies, tumor necrosis
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type II, Animals, Antineoplastic Agents, Killer Cells, Natural, Mice, Inbred BALB C, Mice, Nude, Neoplasms, T-Lymphocytes, Cytotoxic, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Smad2 Protein, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1634
- The paper
- Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., Burtrum, D., Wang, S., Surguladze, D., Ng, S., Griffith, H., Balderes, P., Doody, J., Schwartz, J. D., Youssoufian, H., . . . Wu, Y. (2010). Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.